OTCPK:XVIP.F

Stock Analysis Report

Executive Summary

Xvivo Perfusion AB (publ), a medical technology company, develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation.


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Xvivo Perfusion's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XVIP.F has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

XVIP.F

10.2%

US Medical Equipment

9.4%

US Market


1 Year Return

n/a

XVIP.F

2.1%

US Medical Equipment

-6.8%

US Market

Return vs Industry: Insufficient data to determine how XVIP.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how XVIP.F performed against the US Market.


Shareholder returns

XVIP.FIndustryMarket
7 Day0%10.2%9.4%
30 Day-35.6%0.9%-3.9%
90 Dayn/a-12.1%-16.5%
1 Yearn/a2.9%2.1%-4.8%-6.8%
3 Yearn/a57.1%52.9%23.4%15.2%
5 Year113.9%113.9%89.2%69.8%41.3%25.7%

Price Volatility Vs. Market

How volatile is Xvivo Perfusion's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Xvivo Perfusion undervalued compared to its fair value and its price relative to the market?

18.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XVIP.F ($15.6) is trading below our estimate of fair value ($22.28)

Significantly Below Fair Value: XVIP.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XVIP.F is poor value based on its PE Ratio (536.9x) compared to the Medical Equipment industry average (37.5x).

PE vs Market: XVIP.F is poor value based on its PE Ratio (536.9x) compared to the US market (12.2x).


Price to Earnings Growth Ratio

PEG Ratio: XVIP.F is poor value based on its PEG Ratio (7.4x)


Price to Book Ratio

PB vs Industry: XVIP.F is overvalued based on its PB Ratio (4.6x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Xvivo Perfusion forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

72.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XVIP.F's forecast earnings growth (72.2% per year) is above the savings rate (1.7%).

Earnings vs Market: XVIP.F's earnings (72.2% per year) are forecast to grow faster than the US market (13.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: XVIP.F's revenue (28.1% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: XVIP.F's revenue (28.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XVIP.F's Return on Equity is forecast to be low in 3 years time (14.7%).


Next Steps

Past Performance

How has Xvivo Perfusion performed over the past 5 years?

22.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XVIP.F has high quality earnings.

Growing Profit Margin: XVIP.F's current net profit margins (2.2%) are lower than last year (6.8%).


Past Earnings Growth Analysis

Earnings Trend: XVIP.F's earnings have grown significantly by 22.5% per year over the past 5 years.

Accelerating Growth: XVIP.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: XVIP.F had negative earnings growth (-61.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (1%).


Return on Equity

High ROE: XVIP.F's Return on Equity (0.9%) is considered low.


Next Steps

Financial Health

How is Xvivo Perfusion's financial position?


Financial Position Analysis

Short Term Liabilities: XVIP.F's short term assets (SEK259.9M) exceed its short term liabilities (SEK52.6M).

Long Term Liabilities: XVIP.F's short term assets (SEK259.9M) exceed its long term liabilities (SEK4.4M).


Debt to Equity History and Analysis

Debt Level: XVIP.F is debt free.

Reducing Debt: XVIP.F had no debt 5 years ago.

Debt Coverage: XVIP.F has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: XVIP.F has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Xvivo Perfusion's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XVIP.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XVIP.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XVIP.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XVIP.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XVIP.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Magnus Nilsson (63yo)

9.25s

Tenure

kr9,173,000

Compensation

Dr. Magnus Nilsson, Ph.D., has been the Chief Executive Officer of Xvivo Perfusion AB since 2011. Dr. Nilsson served as the Chief Executive Officer and President of Vitrolife AB (publ) from January 2003 to ...


CEO Compensation Analysis

Compensation vs Market: Magnus's total compensation ($USD901.19K) is below average for companies of similar size in the US market ($USD1.51M).

Compensation vs Earnings: Magnus's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Magnus Nilsson
MD & CEO9.25yrskr9.17m0.75% SEK2.5m
Christoffer Rosenblad
CFO, Deputy CEO8.25yrsno data0.20% SEK666.4k
Henrik Isaksson
Operations Director1.5yrsno datano data
Christer de Flon
no datano datano data
Pär-Ola Larsson
Marketing and Sales Director of EMEA & Pacific4.33yrsno data0.0068% SEK22.1k

6.3yrs

Average Tenure

50yo

Average Age

Experienced Management: XVIP.F's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gösta Johannesson
Chairman of the Board2yrskr205.00k0.0075% SEK24.5k
Dag Andersson
Director1yrno data0.011% SEK36.8k
Camilla Öberg
Director3.92yrskr130.00k0.0040% SEK13.2k
Folke Nilsson
Director7.25yrskr130.00kno data
Yvonne Mårtensson
Director2yrskr130.00k0.011% SEK36.8k
Alan Raffensperger
Director2yrskr130.00kno data

2.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: XVIP.F's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Xvivo Perfusion AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xvivo Perfusion AB (publ)
  • Ticker: XVIP.F
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr3.245b
  • Listing Market Cap: kr325.904m
  • Shares outstanding: 26.60m
  • Website: https://www.xvivoperfusion.com

Number of Employees


Location

  • Xvivo Perfusion AB (publ)
  • Box 53015
  • Gothenburg
  • Västra Götaland County
  • 400 14
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XVIVOOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKOct 2012
XVIP.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDOct 2012
0RKLLSE (London Stock Exchange)YesShare CapitalGBSEKOct 2012
XVIVOSBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKOct 2012

Biography

Xvivo Perfusion AB (publ), a medical technology company, develops solutions and systems for selecting usable organs and maintaining them in optimal condition pending transplantation. The company offers XVIVO Perfusion System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex-vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex, a buffered extracellular colloid-based electrolyte preservation solution; Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. Xvivo Perfusion AB (publ) was founded in 1998 and is headquartered in Gothenburg, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/10 01:04
End of Day Share Price2020/04/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.